- The global pulmonary drug delivery technologies market which was $19.6 billion in 2010 is expected to be around $22.5 billion by 2011. This global market is further projected to reach nearly $44 billion by 2016 at a compound annual growth rate (CAGR) of 14.3%.
- The market for metered dose inhalers (MDIs) was $12.5 billion in 2010 and will reach $14.4 billion by the end of 2011. BCC forecasts this market will grow to $29.8 billion by 2016 at a CAGR of 15.7%.
- The market for dry powder inhalers (DPIs) was $6.6 billion in 2010. This market is expected to increase to $7.5 billion in 2011 and reach $13.4 billion by 2016 at a CAGR of 12.3%.
STUDY GOALS AND OBJECTIVES
This BCC market research report, Pulmonary Drug Delivery Systems: Technologies and Global Markets, provides a detailed overview and thorough analysis of the present and future global market for pulmonary drug delivery technologies. This report analyzes in detail the pulmonary drug delivery technologies that are available and currently used and their markets. This report includes products in this market and detailed analyses of the markets and competitive environments. It also analyzes current and future market prospects. The report provides a comprehensive review of emerging pulmonary drug delivery technologies, particularly with regard to inhaled drug delivery systems. The analysis reviews technological developments, product innovations, and recent strategic industry activities of major players across different product categories. It reviews their strengths and weaknesses, opportunities, and the threats facing various devices and drugs in this market space. The report also reviews developments already on the market, major issues involved in the research and development (R&D) of more effective devices for drug delivery to the lungs, and new products in development.
REASONS FOR DOING
Pulmonary drug delivery has emerged as a more relevant alternative for delivering drugs. Respiratory conditions such as asthma, chronic obstructive pulmonary, and emphysema disease are therapeutic areas of the pulmonary sector. However, recent technological advancements have applied the application of pulmonary devices to the treatment of nonrespiratory conditions such diabetes and migraines. Advancements in formulating technology are expected to push sales of dry powder inhalers, replacing metered-dose inhalers to a large extent. Pulmonary delivery of drugs for the treatment of respiratory diseases stems from the fact that topical drug deposition to the infected lung gives a fast therapeutic effect and reduces side effects associated with key drugs. There is a need to understand the trends in this market, currently available devices and their problems, and the latest developments for drug delivery to the lungs.
SCOPE AND FORMAT
The report reviews global markets for drug delivery technologies and new developments, and forecasts trends for use of current devices for drug delivery and for safety and toxicology through 2016. The report presents important devices, technologies, and the latest developments, market share by device and disease type, current products on the market, market share by company or product, and statistical information for types of respiratory diseases prevalent worldwide, with special emphasis on the U.S. market. The report also includes current issues and trends affecting the industry including costs, and factors influencing demand will be discussed. The report covers products in development, new technologies, trends, alliances, patents, and mergers. The report offers market data with respect to segments and geography. It also provides market trends with respect to drivers, restraints, and opportunities.
This report is an exhaustive study of the worldwide drug delivery market, giving crucial statistics and analysis on existing technologies, the latest trends, market structure, market size, key drug segments, important trends in technology development, major opportunities, and market shares of key players and drugs. This report may prove crucial for drug development companies in drug delivery space, potential investors in the concerned sector. This report shows devices currently being used for drug delivery to the lungs, new developments, spending trends, and revenue prospects for these technologies. The report provides market data for 2010 to 2016 and also covers commercial prospects for pulmonary devices and current inhalers in use and their future.
Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, industry news, and developments and access to paid databases. The base year of the report is 2010, with forecast data provided through 2016. Historical, base year, and forecast data are provided for each market segment of this report. The report provides a comprehensive review of emerging drug delivery technologies, particularly with regard to inhaled drug delivery systems. The new analysis reviews technological developments, product innovations/introductions, and recent strategic industry activities of major players across various product categories. Growth rates are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D, and current product growth.
Usha Nagavarapu is an experienced pharmaceutical professional with scientific and alliance development experience. She has more than 10 years of drug and device product development and alliance management experience. She has managed preclinical discovery programs from target identification through design of Phase I testing, including Investigational New Drug (IND)-enabling studies, and assisted out-licensing and portfolio development activities. Strong focus areas include oncology, dermatology, and cardiovascular diseases. She also has extensive experience working with early startups to fulfill operational obligations while minimizing overall operational cost and burdens.